Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ENO2 sustains cancer stemness and metastatic competence through a phosphoenolpyruvate-dependent metabolic axis in triple-negative breast cancer.

Cell death & disease·2026
Same author

Amplified Spontaneous Emission Enhancement in FAPbI<sub>3</sub> Nanocrystal Films via PMMA and Mechanical Tunability on Flexible PET.

ACS applied materials & interfaces·2026
Same author

Zerumbone from Zingiber zerumbet (L.) Roscoe ex Sm. ameliorates atopic dermatitis by regulating the MAP kinase/NF-κB, Akt, and STAT pathways.

Journal of ethnopharmacology·2026
Same author

Comparative Analysis of Temperature-Dependent Endocytic Regulation of Notch Signaling in Chick and Mouse Neural Progenitors.

Cells, tissues, organs·2026
Same author

Efficient Microwave-Assisted Palladium-Catalyzed Selective <i>N</i>-Arylation of Anilines with 2,3-Dihalopyridines in Water.

Materials (Basel, Switzerland)·2026
Same author

Exploring the impact of age of onset on stereoacuity in patients with myasthenia gravis.

Frontiers in ophthalmology·2026

Related Experiment Videos

Xanthine oxidase inhibitory lanostanoids from Ganoderma tsugae.

Kai-Wei Lin1, Yen-Ting Chen, Shyh-Chyun Yang

  • 1Faculty of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Fitoterapia
|June 18, 2013
PubMed
Summary

Two new lanostanoids from Ganoderma tsugae, tsugaric acids D and E, show potential. Compound 1 inhibits xanthine oxidase (XO), while compound 5 protects skin cells from UV damage and enhances cisplatin

Keywords:
AntioxidantCytotoxicityGanoderma tsugaeLanostanoidsPhotodamage

Related Experiment Videos

Area of Science:

  • Natural Products Chemistry
  • Pharmacology
  • Dermatology

Background:

  • Ganoderma tsugae is a mushroom with potential medicinal properties.
  • Lanostanoids are a class of natural compounds with diverse biological activities.
  • Xanthine oxidase (XO) plays a role in gout and inflammation.
  • UVB radiation causes skin damage and photodamage.

Purpose of the Study:

  • To isolate and characterize new lanostanoids from Ganoderma tsugae.
  • To evaluate the inhibitory effects of isolated compounds on xanthine oxidase (XO) activity.
  • To assess the protective effects of isolated compounds against UVB-induced photodamage in human keratinocytes.
  • To investigate the potential of isolated compounds to enhance the efficacy of cisplatin chemotherapy.

Main Methods:

  • Isolation and structure elucidation of lanostanoids using spectroscopic methods.
  • In vitro assays to determine xanthine oxidase (XO) inhibitory activity (IC50 values).
  • In vitro assays to assess protection of human keratinocytes against UVB-induced damage.
  • Cytotoxicity assays to evaluate the combined effects of isolated compounds and cisplatin.

Main Results:

  • Two new lanostanoids, tsugaric acid D (1) and tsugaric acid E (2), were isolated and characterized.
  • Compound 1 and known compounds 3 and 6 demonstrated significant xanthine oxidase (XO) inhibitory effects.
  • Known compound 5 exhibited protective effects against UVB-induced photodamage in human keratinocytes.
  • Compound 1 enhanced the cytotoxicity of cisplatin in human keratinocytes, suggesting potential for combination therapy.

Conclusions:

  • Tsugaric acids D and E are novel lanostanoids from Ganoderma tsugae.
  • Compound 1 shows promise as a xanthine oxidase (XO) inhibitor.
  • Compound 5 offers potential for photoprotection.
  • Compound 1 may enhance cisplatin's therapeutic efficacy and reduce resistance and side effects in cancer treatment.